Clene Inc. (CLNN) News
Filter CLNN News Items
CLNN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CLNN News Highlights
- CLNN's 30 day story count now stands at 8.
- Over the past 14 days, the trend for CLNN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about CLNN are CNM, IBN and CL.
Latest CLNN News From Around the Web
Below are the latest news stories about CLENE INC that investors may wish to consider to help them evaluate CLNN as an investment opportunity.
Clene Announces New Data from HEALEY ALS Platform TrialLOS ANGELES, CA - (NewMediaWire) - December 22, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Clene (NASDAQ: CLNN) (along with its subsidiaries, "Cl... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning! |
Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label ExtensionCNM-Au8 30mg treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo (18 months from randomization, p=0.023)60% decreased risk of long-term all-cause mortality (>18 months, p=0.0167) in participants originally randomized to CNM-Au8 30mg compared to those originally randomized to placebo using the rank-preserving structural failure time model (RPSFTM) CNM-Au8 30mg had greater overall treatment effect in delaying the time to morbid |
Clene Provides Update on ALS Clinical Development Meeting With FDASALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today provided an ALS regulatory update from its recent meeting with the U.S. Food and Drug Admini |
How Clene CNM-Au8(R) Takes Advantage of Gold Nanocrystals to Target Neurodegenerative DisordersLOS ANGELES, CA - (NewMediaWire) - December 19, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Clene, a late clinical-stage biopharmaceutical company... |
Clene Lead Drug Candidate Featured in Peer-Reviewed PublicationLOS ANGELES, CA - (NewMediaWire) - December 15, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Clene (NASDAQ: CLNN), a late clinical-stage biopharmac... |
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative DiseasesJournal of Nanobiotechnology publication describes results from the successful Phase 2 REPAIR clinical studies that measured changes in brain energy metabolites in multiple sclerosis and Parkinson’s disease with CNM-Au8® treatment Data show significant increase in brain NAD+/NADH ratio from baseline, the studies’ primary endpoint, following 12 weeks of daily oral dosing of CNM-Au8CNM-Au8 treatment resulted in favorable modulation of additional brain energy metabolites that have been shown to be |
Clene's Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS PatientsLOS ANGELES, CA - (NewMediaWire) - December 12, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Clene (NASDAQ: CLNN), together with its wholly owned s... |
Nobel Prize in Chemistry's Spotlight on Nanotechnology Shines Light on Clene Efforts to Develop Catalytically Active NanoparticlesLOS ANGELES, CA - (NewMediaWire) - December 8, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.The 2023 Nobel Prize in Chemistry, awarded to Moungi G.... |
Clene Capitalizing on Promising Chemical and Therapeutic Properties of NanocrystalsLOS ANGELES, CA - (NewMediaWire) - November 23, 2023 - (InvestorBrandNetwork via NewMediaWire) - This original article is powered by IBN, a financial news, content creation and publishing company.Clene is focused on developing and commercializing nov... |